PARIS: A blockbuster anti-obesity and diabetes drug could cost as little as US$3 per month to manufacture once it goes off patent later this month, researchers said on Friday (Mar 6), providing a major opportunity to boost health in low and middle-income countries. Semaglutide, the active molecule in Novo Nordisk's Ozempic and Wegovy treatments , leads to considerable weight loss in patients and thus can provide major help in managing diabetes and other medical problems related to obesity.